ACVR1 and anemia: The beneficial effects of MMB in addressing anemia and reducing the need for blood transfusions are associated with its ability to suppress the production of hepcidin mediated by Activin A receptor type I (ACVR1) also known as activin receptor-like kinase-2 (ALK2).